Skip to main content

B7-33

No sources yet

An index of captured practitioner sources, not a completed evidence summary. Unchecked figures and empty sections are omitted. See the library review status.

Source summary generated November 6, 2026; this date does not indicate completed review.

Tissue researchAliases: relaxin B7-33, single-chain relaxin
Track your own protocol free →

Quotes from three independent practitioners, with their sources. Research context only.

What it is and how it works

From the published literature on B7-33; the papers are listed at the end. Research summary, not a recommendation.

What it is

B7-33 is a laboratory-designed fragment of the B chain of human relaxin-2, a natural hormone made of two amino-acid chains joined by disulfide bonds. Researchers shortened it to a single-chain peptide that is far easier and cheaper to make than the two-chain hormone. It has been studied in cells and rodents; no human trial of B7-33 was found in PubMed as of 2026-11-06.

How it works

B7-33 binds RXFP1, the relaxin receptor found on cells of blood vessels, heart, lung and kidney, but it switches on a narrower set of signals than natural relaxin (it favors the ERK1/2 pathway over the cAMP pathway, two cell-signaling routes). In rodent models of heart and lung disease it prevented or reversed fibrosis (scar-like tissue buildup), and in one mouse heart model it reduced left ventricular fibrosis sooner than the blood-pressure drug perindopril. Unlike relaxin, it did not promote prostate tumor growth in mice in the original study.

What it has been studied for

  • Heart and lung fibrosis in rodent models
  • Cardioprotective effects in a mouse cardiomyopathy model
  • Blood vessel function in rats
  • Reducing scar-like capsules around implants (mouse study of a drug-releasing coating)

Strength of the evidence

Animal and lab studiesPublished work is limited to cell studies, rodent models and a mouse implant-coating study; no human data were found.

What the literature reports on safety

No human safety data exist. Researchers noted that natural relaxin's strong cAMP signaling was linked to tumor-promoting concerns in lab work and that B7-33 did not show this in one mouse prostate model, which is a single animal finding. B7-33 is not an approved drug and is not named on the FDA compounding-substances page (content current as of 2026-04-22).

Key papers

  1. Single chain peptide agonists of relaxin receptors. (opens in a new tab)

    Review · Praveen P, Kocan M, et al. · Molecular and Cellular Endocrinology (2019) · PMID 30641102

    Reviewed how relaxin family peptides were minimized into single-B-chain agonists such as B7-33 and described their effects in cell and animal models.

  2. A single-chain derivative of the relaxin hormone is a functionally selective agonist of the G protein-coupled receptor, RXFP1. (opens in a new tab)

    Lab (in vitro) · Hossain MA, Kocan M, et al. · Chemical Science (2016) · PMID 30155023

    B7-33 bound RXFP1 and preferentially activated the ERK pathway over cAMP, prevented or reversed fibrosis in three rodent models, and unlike relaxin did not promote prostate tumor growth in mice.

  3. B7-33 replicates the vasoprotective functions of human relaxin-2 (serelaxin). (opens in a new tab)

    Animal study · Marshall SA, O'Sullivan K, et al. · European Journal of Pharmacology (2017) · PMID 28478069

    In rats, B7-33 and serelaxin both enhanced bradykinin-mediated relaxation of the mesenteric artery, showing B7-33 reproduced relaxin's blood vessel effects.

  4. The single-chain relaxin mimetic, B7-33, maintains the cardioprotective effects of relaxin and more rapidly reduces left ventricular fibrosis compared to perindopril in an experimental model of cardiomyopathy. (opens in a new tab)

    Animal study · Alam F, Gaspari TA, et al. · Biomedicine & Pharmacotherapy (2023) · PMID 36753958

    In mice with isoprenaline-induced cardiomyopathy, B7-33 kept relaxin's heart-protective effects and reduced left ventricular fibrosis more rapidly than perindopril.

  5. Coatings Releasing the Relaxin Peptide Analogue B7-33 Reduce Fibrotic Encapsulation. (opens in a new tab)

    Animal study · Welch NG, Mukherjee S, et al. · ACS Applied Materials & Interfaces (2019) · PMID 31713411

    A biodegradable coating that slowly released B7-33 kept the peptide active at RXFP1 and reduced the fibrous capsule around implants in mice.

Sources checked: PubMed (E-utilities abstracts for every PMID), FDA compounding-substances page (current as of 2026-04-22), written 2026-11-06.

No sources yet

None of the three teachers' sources we have indexed discuss B7-33 yet. This page will fill in as sources are added.

Deeper guided audio lives on What Am I Appreciating Now (leaves this site, opens in a new tab). What Am I Appreciating Now is a separate site run by the same operator; it sells meditation and hypnosis sessions.

Disclaimer: for research purposes only

All content on this page is for research and educational purposes only and is not intended as medical advice. Always consult a qualified healthcare provider before starting any peptide or hormone protocol. You take responsibility for your own protocol.If your path includes peptides, you buy them yourself from an independent licensed provider through a member co-op; we take nothing. How independent access works.

B7-33 — Hunter, Taylor, Bachmeyer | Reset Biology